Stages in reproduction particularly vulnerable to xenobiotic hazards and nutritional deficits.
Biochemical research has identified many failures in reproductive processes with specific nutrient deficits, xenobiotics and some infectious illnesses. This has led to some effective safeguards. During meiosis and fertilization, as genetic material divides and rearranges, it is exposed and open to mutation. A nutritionally unfavourable environment is a major risk factor. At stages of rapid cell division, differentiation and organisation, as in the embryo and later in the fetal brain, the child's survival, completeness and future health and ability are at stake. From months before conception, reproduction needs preparing for, especially with today's environmental pollution, even entering the foodchain. Care from before conception can contribute not only to the child's healthy basis for life, full development of brain, eyesight and other complex attributes, but also to the health of at least the subsequent generation. Since the female baby's oocytes are being formed while she is still in the womb, the grandmother's nutritional status, around the time of conceiving a daughter, can permanently affect a grandchild. Recent insights into evolution, particularly of the brain, give us fresh indications of dietary needs to fulfil human potential for health and acuity. Despite the hazards, nature is remarkably successful. This paper is not designed to alarm but to help attainment of full genetic potential. With healthy parents serious malformations are a low percentage. The numbers of babies with avoidable disorders, however, calls urgently for action, especially in our own inner cities and in developing countries where there is inadequate nutrition. Action will more than justify itself, including financially. It will reward handsomely.
House
S
S
shhouse@dircon.co.uk
D001921:Brain / Q000187:drug effects / Q000196:embryology / Q000254:growth & development; D004281:Docosahexaenoic Acids / Q000378:metabolism; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D004739:England; D005260:Female; D005317:Fetal Growth Retardation / Q000209:etiology / Q000517:prevention & control; D005333:Fetus / Q000002:abnormalities / Q000187:drug effects* / Q000196:embryology; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D006293:Health Promotion; D006801:Humans; D009748:Nutrition Disorders / Q000150:complications; D009752:Nutritional Status / Q000502:physiology*; D016742:Preconception Care; D011247:Pregnancy; D011322:Primary Prevention; D012098:Reproduction / Q000502:physiology*; D013997:Time Factors; D015262:Xenobiotics / Q000009:adverse effects* / Q000494:pharmacology
D015262:Xenobiotics; D004281:Docosahexaenoic Acids; D005492:Folic Acid